GlaxoSmithKline news from FierceBiotech
NewsGlaxoSmithKline to axe 850 jobs in R&D
Moving forward with its restructuring plan, GlaxoSmithKline announced to employees via email today that it would be laying off as many as 850 (6 percent) employees in its research and development... Read more...
GSK ends NPS's osteoporosis drug study
Bad news for NPS Pharmaceuticals: the company announced late Thursday that its partner GlaxoSmithKline would abandon a Phase II study of Ronacalaret, an osteoporosis drug. According to SEC filings... Read more...
GSK: Ovarian cancer drug positive in Phase II
GlaxoSmithKline says it will push pazopanib into late-stage studies for ovarian cancer after a mid-stage trial produced positive data on a key biomarker. Only 35 patients participated in the Phase II... Read more...
GSK founds oncology unit
Last December GlaxoSmithKline said that it had more plans to shake up R&D. The company had already created Centres of... Read more...
GSK signs $1.5 drug dev deal with Cellzome
GlaxoSmithKline is teaming up with Cellzome, which is developing kinase-targeted drugs, in a deal that could be worth up to $1.5 billion. The pact will target inflammatory diseases such as rheumatoid... Read more...
GSK's Viehbacher picked as Sanofi CEO
When GlaxoSmithKline's Chris Viehbacher (photo) announced his plans to leave the company, everyone wondered where he would head... Read more...
GSK, Valeant ink $820M epilepsy deal
Valeant Pharmaceuticals will pocket a $125 million upfront fee from GlaxoSmithKline in exchange for a collaboration deal on the epilepsy drug
Chemists laid off at GlaxoSmithKline
GlaxoSmithKline's June announcement that it was cutting 350 jobs worldwide is coming to fruition.... Read more...
GSK, Genmab report strong ofatumumab data
So far, it looks like GlaxoSmithKline's $2.1 billion deal for HuMax-CD20 was money well spent. Inerim data from a Phase... Read more...
GSK, Harvard ink stem cell research pact
In another instance of the industry teaming up with academia, GlaxoSmithKline and Harvard Stem Cell Institute (HSCI) announced that they have signed a five-year, $25 million pact to research and... Read more...
| Press ReleasesDisclosure of Shareholdings in Accordance with Stock Market Rules Disclosure of Shareholdings in Accordance with Stock Market Rules Geneva, Switzerland, 26 September 2008- Addex Pharmaceuticals (SWX:ADXN) announced today that on September 25, 2008, S.R. One Ltd, Read more >> AHF Advocacy Spurs GSK to Suspend Fear-Mongering AIDS Drug AdsAHF Advocacy Spurs GSK to Suspend Fear-Mongering AIDS Drug Ads AHF Runs Pieces Headlined "GSK: Worst Drug Ads Ever." The Issue Prompts Articles in the Wall Street Journal and Philadelphia Inquirer; Read more >> New data for GlaxoSmithKline's pre-pandemic H5N1 influenza vaccine, PrepandrixTM, show administration flexibility for pandemicNew data for GlaxoSmithKline's pre-pandemic H5N1 influenza vaccine, PrepandrixTM, show administration flexibility for pandemic planning PrepandrixTM, Europe's only approved pre-pandemic influenza Read more >> Antitrust: Commission welcomes Court decision on parallel trade in the pharmaceutical sectorBrussels, 16th September 2008 Antitrust: Commission welcomes Court decision on parallel trade in the pharmaceutical sector The European Commission welcomes today's ruling of the European Court of Read more >> GSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira for Restless Legs SyndromeGSK and XenoPort Announce Submission of New Drug Application Requesting FDA Approval of Solzira for Restless Legs Syndrome Submission Based on Results from Pivotal Trials Evaluating Efficacy, Safety Read more >> |
Get more GlaxoSmithKline coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
